| Name | Value |
|---|---|
| Revenues | 1.3M |
| Cost of Revenue | 0.3M |
| Gross Profit | 0.9M |
| Operating Expense | 19.2M |
| Operating I/L | -18.3M |
| Other Income/Expense | 3.2M |
| Interest Income | 0.8M |
| Pretax | -15.1M |
| Income Tax Expense | 2.1M |
| Net Income/Loss | -17.1M |
Nyxoah S.A. is a medical technology company specializing in solutions for sleep disordered breathing conditions. Its flagship product, the Genio system, is a CE-Marked hypoglossal neurostimulation therapy designed to treat moderate to severe obstructive sleep apnea. The company generates revenue through the development and commercialization of its innovative medical devices, providing patients with a patient-centric approach to addressing their sleep apnea needs.